Roche Q3 results show steep fall-off in COVID product sales

Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p

Priority review sets up Feb verdict on Sanofi, Sobi haemophi...

The FDA will carry out a speedy review of Sanofi and Sobi's once-weekly haemophilia A treatment efanesoctocog alfa (Bivv001), with a decision now

Sanofi trumpets data with haemophilia treatment duo at ISTH

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at th

Novo Nordisk's concizumab hits mark in haemophilia, but dosi...

Novo Nordisk has reported phase 3 results with its concizumab drug for haemophilia A or B, showing efficacy in the prevention of bleeding events that will support regulatory filings startin

Sanofi, Sobi eye filings for once-weekly haemophilia A thera...

Sanofi and Sobi's haemophilia partnership has been under competitive pressure from new therapies like Roche's antibody Hemlibra, so the two companies are hoping a new long-acting drug candi

Roche raises 2019 outlook, shrugging off biosimilar threat